Organogenesis will study combat injury treatments

Organogenesis Inc., a Canton biotechnology company that makes artificial skin, said today that it is part of a large consortium that aims to develop regenerative medicine therapies to treat battlefield injuries.

The consortium is led by the Institute for Regenerative Medicine at Wake Forest University's Baptist Medical Center, and it will be awarded $42.5 million over five years by the US Army Institute of Surgical Research, Organogenesis said.

Organogenesis chief executive Geoff MacKay (left) said in a statement that he believed his company's experience in regenerative medicine technology will be beneficial to the consortium.

For recent Globe coverage of Organogenesis, click here.
(By Chris Reidy, Globe staff)